Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Upgrades According to Baird, the prior rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was changed from Neutral to Outperform. Ultragenyx Pharmaceutical earned $2.43 in the third quarter, comp

Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

03:43pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Alkermes plc (NASDAQ:ALKS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Richard Pops - CEO Iain Brown - CFO Todd Nicho
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes, Allakos See Activist Action

06:35pm, Friday, 14'th Oct 2022
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Upgrades For Enviva Inc (NYSE:EVA), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Enviva had an EPS of $0.26, compared to year-ago quarter EPS of $0.24. The curren
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.2

Alkermes: Nothing Stands Out As Interesting

03:02pm, Monday, 26'th Sep 2022
Alkermes plc has a slew of revenue earning products in CNS. It is refocusing itself on oncology assets.

Alkermes (ALKS) Gains As Market Dips: What You Should Know

09:50pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Alkermes (ALKS) closed the most recent trading day at $24.51, moving +0.62% from the previous trading session.

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

02:20pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

12:46pm, Thursday, 18'th Aug 2022 Zacks Investment Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

12:40pm, Thursday, 18'th Aug 2022 Zacks Investment Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE